<DOC>
	<DOC>NCT00359177</DOC>
	<brief_summary>The purpose of the study is to evaluate how subjects with mild or moderate liver problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.</brief_summary>
	<brief_title>Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criteria: Healthy or have mild or moderate hepatic impairment Females: Nonchildbearing (hysterectomy, bilateral oophorectomy, postmenopausal), childbearing (negative pregnancy test, abstinence, doublebarrier contraception, vasectomized partner) Negative for Hepatitis B and C(healthy subjects) Negative drug, alcohol and HIV tests Exclusion criteria: Fluctuating or rapidly deteriorating hepatic function or abnormal kidney function Encephalopathy Active peptic ulcer disease Drug or alcohol abuse Pregnant or lactating Esophageal bleeding Heart failure Infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>emesis liver problems hepatic impairment GW679769</keyword>
</DOC>